In the oral presentation, the investigators reported ongoing improved survival compared to historical controls, with 3 out of ...

AMPLIFY-7P Phase 2 randomized study anticipated to complete enrollment in Q4 2024; formal interim analysis of disease-free survival ("DFS") expected in H1 2025Poster presentation at the Society for Im ...

Lincoln Melling, from Shevington, died on Monday, only a few days after his 11th birthday. He is survived by his parents Dan ...

Notes payable, plus accrued interest, totaled approximately $6.9 million. The current portion of the notes payable plus ...

Enrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of scheduleSITC 2024 ...

Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient ...

Detailed price information for Corvus Pharma Com (CRVS-Q) from The Globe and Mail including charting and trades.

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September and, according to ...

Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study of uliledlimab ...

Good afternoon and welcome to today's conference call for Omeros Corporation. (Operator Instructions) Please be advised that this call is being recorded at the company's request and a replay will be ...

HUYABIO International today announced the presentation of new patient data for HBI-3000, an antiarrhythmic drug (AAD) with a unique protective profile for the treatment of atrial fibrillation (AF), ...

This year's award marks 30 years since clinicians first used ECP to successfully treat chronic graft versus host <a target=_bla ...